Athena Global Technologies Ltd-$
Athena Global Technologies allots 7,00,000 warrants to promoter at Rs. 84 each
BOARD
● No Immediate Change
MEDIUM RISK
📅 Filed on BSE: 13 Apr 2026, 02:24 PM IST · BSE ID: e938b966-c8d5-447f-8077-67f2ee6678d1
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved selling warrant certificates to its promoter that can be converted into shares later, with Rs. 1,47,00,000 collected upfront.
🤖 AI Summary
- Board allotted 7,00,000 convertible share warrants to promoter Karthikeya Manchala on 13 April 2026
- Issue price Rs. 84 per warrant including Rs. 74 premium per share
- 25% upfront consideration received: Rs. 1,47,00,000 as per SEBI ICDR Regulations 2018
- Warrants convertible into equal equity shares upon balance receipt within stipulated time
- Follows EGM shareholder approval 25 March 2026 and BSE in-principle approval 1 April 2026
🔢 Key Numbers - exact figures from BSE filing, not rounded
Convertible share warrants allotted
7,00,000
Issue price per warrant
Rs. 84
Upfront consideration received (25%)
Rs. 1,47,00,000
🏢 How This Affects the Company
Company received Rs. 1,47,00,000 as 25% upfront consideration. Balance amount due on conversion. No immediate impact on paid-up capital until warrant conversion occurs.
👥 What This Means For Shareholders
✅
Action Required
No action required. Monitor warrant conversion announcements and disclosure of balance payment receipt.
👤
Who Is Affected
All existing equity shareholders will face dilution equal to 7,00,000 new shares upon warrant conversion. Promoter ownership will increase by warrant conversion amount.
🔍
Management Signal
Promoter capital injection through warrant structure indicates management confidence in company growth, while warrant format preserves cash flexibility by deferring balance payment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Warrant conversion announcement — track balance payment receipt and conversion into equity shares
Q1 FY27 results — monitor shareholding pattern change when warrants convert to equity
Board meeting outcome — watch for disclosure of balance consideration amount and conversion timeline
MEDIUM RISK
Balance consideration amount and conversion tenure not disclosed. Dilution of 7,00,000 shares on conversion materially impacts EPS. Execution risk on balance payment receipt.
💡 Investor Takeaway
Promoter Karthikeya Manchala committed Rs. 1,47,00,000 upfront (25% of total) for 7,00,000 convertible warrants at Rs. 84 each. Conversion into equity pending balance payment. No immediate paid-up capital change or dilution until exercise.
⚖️ Strengths & Concerns
✅ Positives
- Promoter capital commitment of Rs. 1,47,00,000 demonstrates confidence in company direction and growth strategy
- Warrant structure provides capital flexibility — balance due only upon conversion into equity shares
⚠️ Concerns
- 7,00,000 additional shares upon conversion will dilute existing shareholder ownership when exercised
- Balance consideration amount and conversion timeline not specified in filing — triggers execution risk
📅 Company Track Record
On 31 March 2026, Athena Global's board acquired 100% of MedleyMed Healthcare as wholly-owned subsidiary and divested Medley Medical Solutions, consolidating group healthcare operations. Current warrant allotment supports promoter capital participation in consolidated structure.
Based on publicly available historical data. For context only.